257 related articles for article (PubMed ID: 30008443)
1. Ocrelizumab for multiple sclerosis.
Drug Ther Bull; 2018 Jul; 56(7):80-84. PubMed ID: 30008443
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab: First Global Approval.
Frampton JE
Drugs; 2017 Jun; 77(9):1035-1041. PubMed ID: 28523586
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and safety of natalizumab in multiple sclerosis: data of the first five years from the TOP (Tysabri Observational Program)].
Magdolna S
Ideggyogy Sz; 2014 May; 67(5-6):211-2. PubMed ID: 25087382
[No Abstract] [Full Text] [Related]
7. [Natalizumab retreatment: effectiveness and long-term safety in multiple sclerosis in the STRATA study].
Csépány T
Ideggyogy Sz; 2014 Jul; 67(7-8):277-9. PubMed ID: 25509370
[No Abstract] [Full Text] [Related]
8. Disease-modifying therapies for multiple sclerosis.
De Angelis F; John NA; Brownlee WJ
BMJ; 2018 Nov; 363():k4674. PubMed ID: 30482751
[No Abstract] [Full Text] [Related]
9. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab: A Review in Multiple Sclerosis.
Syed YY
CNS Drugs; 2018 Sep; 32(9):883-890. PubMed ID: 30171504
[TBL] [Abstract][Full Text] [Related]
11. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
12. [Ocrelizumab for treatment of multiple sclerosis].
Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
[TBL] [Abstract][Full Text] [Related]
13. Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab.
Greve AS; Prakash S; Krag S; Randers E
J Nephrol; 2023 Apr; 36(3):659-661. PubMed ID: 36414886
[TBL] [Abstract][Full Text] [Related]
14. Ocrelizumab (Ocrevus) for MS.
Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
[No Abstract] [Full Text] [Related]
15. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
16. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis].
Sastre-Garriga J; Montalban X
Neurologia; 2011 Nov; 26(9):556-62. PubMed ID: 21481981
[TBL] [Abstract][Full Text] [Related]
18. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
20. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
